In the Media

InMed’s INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Promising early studies demonstrate INM-901’s neuroprotective effects and an ability

Jerry Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, joins this live panel discussion “Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour podcast. Host Jesse Redmond, Senior Analyst at Water Tower